在高危室性心律失常患者中提高血钾水平
该多中心、开放标签、事件驱动、随机优效性试验在丹麦纳入1200例植入ICD且基线血钾≤4.3 mmol/L的高危室性心律失常患者,1:1随机分为高正常血钾组(通过补钾、盐皮质激素受体拮抗剂或两者联合加饮食指导及标准治疗,目标血钾4.5–5.0 mmol/L)和标准治疗组。中位随访39.6个月,高正常血钾组主要复合终点发生136例(22.7%;7.3事件/100人年),标准治疗组175例(29.2%;9.6事件/100人年),HR 0.76(95%CI 0.61–0.95;P=0.01)。两组因高钾血症或低钾血症住院的发生率相似。结果表明,在此类患者中,治疗性提高血钾水平可显著降低主要复合终点风险。
要点
- 纳入标准为植入ICD且基线血钾≤4.3 mmol/L的高危室性心律失常患者,共1200例,随机1:1分组。
- 高正常血钾组目标血钾4.5–5.0 mmol/L,手段为补钾、盐皮质激素受体拮抗剂或两者联合加饮食指导及标准治疗。
- 主要复合终点(持续性室速或适当ICD治疗、因心律失常或心衰非计划住院>24小时、全因死亡)高正常血钾组22.7% vs 标准治疗组29.2%,HR 0.76(95%CI 0.61–0.95;P=0.01)。
- 两组因高钾血症或低钾血症住院的发生率相似。
- 中位随访39.6个月(四分位距26.4–49.3)。
适用人群与场景
- 植入植入式心律转复除颤器(ICD)且基线血钾≤4.3 mmol/L的高危室性心律失常患者。
- 研究在丹麦多中心开展。
诊断标准与关键阈值
- 高危室性心律失常定义为植入ICD。
- 基线血钾≤4.3 mmol/L为纳入条件。
- 高正常血钾组目标血钾4.5–5.0 mmol/L。
处置流程与药物剂量
- 高正常血钾组:通过补钾、盐皮质激素受体拮抗剂或两者联合,加饮食指导及标准治疗,将血钾提升至4.5–5.0 mmol/L。
- 标准治疗组:仅接受标准治疗。
研究设计与关键结果
- 多中心、开放标签、事件驱动、随机优效性试验,纳入1200例(每组600例),中位随访39.6个月(四分位距26.4–49.3)。
- 主要复合终点(持续性室速或适当ICD治疗、因心律失常或心衰非计划住院>24小时、全因死亡)高正常血钾组136例(22.7%;7.3事件/100人年) vs 标准治疗组175例(29.2%;9.6事件/100人年),HR 0.76(95%CI 0.61–0.95;P=0.01)。
- 因高钾血症或低钾血症住院的发生率两组相似。
证据类型、等级与局限
- 随机优效性试验(POTCAST,NCT03833089),多中心、开放标签、事件驱动。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于植入ICD且基线血钾≤4.3 mmol/L的高危室性心律失常患者,作者结论认为治疗性提高血钾至4.5–5.0 mmol/L可显著降低适当ICD治疗、因心律失常或心衰非计划住院或全因死亡的复合终点风险。
指南或共识出处
- POTCAST试验(ClinicalTrials.gov NCT03833089),由Independent Research Fund Denmark等资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Hypokalemia and even low-normal plasma potassium levels increase the risk of ventricular arrhythmias among patients with cardiovascular disease. An assessment of a strategy of actively increasing plasma potassium levels to the high-normal range is needed.
METHODS: In this multicenter, open-label, event-driven, randomized superiority trial conducted in Denmark, we enrolled participants at high risk for ventricular arrhythmias (defined as those with an implantable cardioverter-defibrillator [ICD]) and with a baseline plasma potassium level of 4.3 mmol per liter or lower. Participants were randomly assigned, in a 1:1 ratio, to a treatment regimen aimed at increasing the plasma potassium level to a high-normal level (4.5 to 5.0 mmol per liter) by means of potassium supplementation, a mineralocorticoid receptor antagonist, or both plus dietary guidance and standard care (high-normal potassium group) or to standard care only (standard-care group). The primary end point was a composite of documented sustained ventricular tachycardia or appropriate ICD therapy, unplanned hospitalization (>24 hours) for arrhythmia or heart failure, or death from any cause, assessed in a time-to-first-event analysis.
RESULTS: Among the 1200 participants who underwent randomization (600 assigned to each group), the median duration of follow-up was 39.6 months (interquartile range, 26.4 to 49.3). A primary end-point event occurred in 136 participants (22.7%; 7.3 events per 100 person-years) in the high-normal potassium group, as compared with 175 participants (29.2%; 9.6 events per 100 person-years) in the standard-care group (hazard ratio, 0.76; 95% confidence interval, 0.61 to 0.95; P = 0.01). The incidence of hospitalization for hyperkalemia or hypokalemia was similar in the two groups.
CONCLUSIONS: Among participants with any cardiovascular disease who had an ICD and were at high risk for ventricular arrhythmias, a treatment-induced increase in plasma potassium levels led to a significantly lower risk of appropriate ICD therapy, unplanned hospitalization for arrhythmia or heart failure, or death from any cause than standard care. (Funded by the Independent Research Fund Denmark and others; POTCAST ClinicalTrials.gov number, NCT03833089.).
参考来源
- Jøns C, Zheng C, Winsløw UCG, et al. Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias. N Engl J Med. 2025. PMID: 40879429. doi:10.1056/NEJMoa2509542
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。